The ADC binds HER2 on target cells, is internalized, and releases the deruxtecan topoisomerase I inhibitor via a cleavable linker, causing DNA damage and apoptosis; the antibody Fc can also mediate ADCC, with potential bystander killing from the membrane-permeable payload.